Abstract: This invention relates generally to viral vectors and viral particles based on Anelloviruses, which can be used to deliver an agent (e.g., an exogenous effector or an endogenous effector, e.g., a therapeutic effector) to a cell (e.g., a cell in a subject to be treated therapeutically). Described herein are anellosomes, anellovectors, and compositions and uses thereof.
Type:
Grant
Filed:
September 29, 2021
Date of Patent:
September 20, 2022
Assignee:
FLAGSHIP PIONEERING INNOVATIONS V, INC.
Inventors:
Simon Delagrave, Fernando Martin Diaz, Avak Kahvejian, Kevin James Lebo, Dhananjay Maniklal Nawandar, Jared David Pitts, Ryan D. Tedstone, Erica Gabrielle Weinstein, Nathan Lawrence Yozwiak
Abstract: The invention discloses an eyelash liquid eyeliner, wherein the raw materials comprise the following components in parts by weight: 50-60 parts of ethyl hexyl acrylate copolymer, 30-40 natural beeswax, 10-12 carnauba wax, 8-12 polyvinylpyrrolidone, 5-7 shellac, 1-3 black talc powder, 20-30 polyvinyl alcohol, 20-30 of silicone resins, 10-12 of codariocalyx motorius saponin extract, 5-7 dual-directional regulation growth promotion factors, 1-3 antifreeze, 1-3 coloring agent, 1-3 preservative, and 5-7 antioxidant. Components in the liquid eyeliner are replaced with natural substances of the natural beeswax, the carnauba wax, the shellac and the like, and the eyelash liquid eyeliner is safe to skin. Besides, organic silicone resins are added, so that the condition that the eyelash liquid eyeliner is broken up when being in contact with water can be effectively avoided, the organic silicone resin can effectively block ultraviolet rays and prevent the ultraviolet rays from destroying roots of eyelashes.
Abstract: Embodiments relate to peptide antagonists of ?c-family cytokines, which is associated with important human diseases, such as leukemia, autoimmune diseases, collagen diseases, diabetes mellitus, skin diseases, degenerative neuronal diseases and graft-versus-host disease (GvHD). Thus, inhibitors of ?c-cytokine activity are valuable therapeutic and cosmetic agents as well as research tools. Traditional approaches to inhibiting yc-cytokine activity involve raising neutralizing antibodies against each individual ?c-cytokine family member/? receptor subunit. However, success has been limited and often multiple ?c-cytokine family members co-operate to cause the disease state. Combinatorial use of neutralizing antibodies raised against each factor is impractical and poses an increased risk of adverse immune reactions. The present embodiments overcome these shortcomings by utilizing peptide antagonists based on the consensus ?c-subunit binding site to inhibit ?c-cytokine activity.
Abstract: The present disclosure provides certain silk-fibroin compositions with particular characteristics and/or properties. In some embodiments, the disclosure provides low molecular weight compositions. In some embodiments, the disclosure provides silk fibroin compositions that comprise an active (e.g., a biological) agent or component. In some embodiments, the disclosure provides low molecular weight silk fibroin compositions that comprise an active (e.g., a biological) agent or component. In some embodiments, an active agent is stabilized in a silk composition, e.g., for a period of time and/or against certain conditions or events. In some embodiments, a component present in a silk fibroin composition may be subject to analysis and/or characterization. In some embodiments, a component present in a silk fibroin composition may be recovered from the composition.
Type:
Grant
Filed:
March 11, 2016
Date of Patent:
July 5, 2022
Assignee:
Trustees of Tufts College
Inventors:
Jonathan A. Kluge, Fiorenzo G. Omenetto, David L. Kaplan
Abstract: Disclosed herein are methods and compositions for inactivating TCR genes, using engineered nucleases comprising at least one DNA binding domain and a cleavage domain or cleavage half-domain in conditions able to preserve cell viability. Polynucleotides encoding nucleases, vectors comprising polynucleotides encoding nucleases and cells comprising polynucleotides encoding nucleases and/or cells comprising nucleases are also provided. Disclosed herein are also methods and compositions for expressing a functional exogenous TCR in the absence of endogenous TCR expression in T lymphocytes, including lymphocytes with a central memory phenotype. Polynucleotides encoding exogenous TCR, vectors comprising polynucleotides encoding exogenous TCR and cells comprising polynucleotides encoding exogenous TCR and/or cells comprising exogenous TCR are also provided.
Abstract: Disclosed herein is a composition for gene delivery which forms into liquid crystals in an aqueous fluid including chitosan and a liquid crystal formation material. The composition of the present invention including chitosan and a liquid crystal formation material improves the relatively low binding strength between chitosan and a gene, and also considerably increases the stability of a chitosan nanocomposite in blood serum, thereby performing highly efficient gene delivery and providing excellent stability, thus being useful as a gene therapeutic agent.
Type:
Grant
Filed:
February 28, 2014
Date of Patent:
May 3, 2022
Assignee:
Chong Kun Dang Pharmaceutical Corp.
Inventors:
Ho Young Hwang, Ji Hye Hwang, Young Nam Lee, Sang Myoung Noh, Min Hyo Ki
Abstract: Methods for introducing exogenous material into a cell are provided, which include exposing the cell to a transient decrease in pressure in the presence of the exogenous material. Also provided are devices for performing the method of the invention.
Abstract: The use of iNOS inhibitors, including aurintricarboxylic acid, dexamethasone and valproic acid, to increase the yield of a variety of viruses in culture, including recombinant herpesviruses is described.
Type:
Grant
Filed:
January 7, 2014
Date of Patent:
April 12, 2022
Assignee:
Genzyme Corporation
Inventors:
Peter Pechan, Jeffery Ardinger, Abraham Scaria, Samuel Wadsworth
Abstract: Methods for introducing exogenous material into a cell are provided, which include exposing the cell to a transient decrease in pressure in the presence of the exogenous material. Also provided are devices for performing the method of the invention.
Abstract: The invention provides compositions and methods useful for the treatment and prevention of conditions associated with myocardial infarction.
Type:
Grant
Filed:
August 4, 2015
Date of Patent:
March 1, 2022
Assignees:
Fundación del Sector Público Estatal Centro Nacional de Investigaciones Oncológicas Carlos III (F.S.P. CNIO), Universität Autónoma de Barcelona
Inventors:
Maria Antonia Blasco Marhuenda, Bruno Bernardes De Jesus, Christian Baer, Rosa María Serrano Ruiz, Fàtima Bosch I Tubert, Eduard Ayuso, Ivan Formentini, Maria Bobadilla, Jacques Mizrahi
Abstract: Described herein are immuno-stimulatory RNA nanostructures (which comprises a single-stranded RNA (ssRNA) molecule, wherein the ssRNA molecule forms at least one paranemic cohesion crossover), as well as compositions and methods of use thereof.
Type:
Grant
Filed:
January 10, 2019
Date of Patent:
February 8, 2022
Assignee:
ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY
Abstract: The present invention is directed to hemostatic compositions comprising at least partially integrated agglomerated oxidized regenerated cellulose (ORC) fibers, fibrinogen, and thrombin and methods of forming a powdered hemostatic composition, comprising the steps of: forming a suspension of a mixture comprising particles of fibrinogen, thrombin, ORC fibers in a non-aqueous low boiling solvent; spraying the suspension through a nozzle onto a substrate, allowing the non-aqueous solvent to evaporate; separating from the substrate and sieving the composition.
Type:
Grant
Filed:
September 7, 2016
Date of Patent:
January 25, 2022
Assignee:
Guangzhou Bioseal Biotech Co., Ltd.
Inventors:
Shuang Chen, Yufu Li, Dengmin Feng, Xiang Wan
Abstract: The present invention relates to T cell receptors (TCRs) which bind the HLA-A*02 restricted peptide GLYDGMEHL (SEQ ID NO: 1) derived from the MAGE-A10 protein. The TCRs of the invention demonstrate excellent specificity profiles for this MAGE epitope. Also provided are nucleic acids encoding the TCRs, cells engineered to present the TCRs, cells harbouring expression vectors encoding the TCRs and pharmaceutical compositions comprising the TCRs, nucleic acids or cells of the invention.
Type:
Grant
Filed:
April 5, 2017
Date of Patent:
December 21, 2021
Assignee:
ADAPTIMMUNE LIMITED
Inventors:
Conor Hayes, Arsen Volkov, Andrew Gerry, Ellen Border, Edward Carter
Abstract: It was revealed that the intravenous administration of HMGB-1 and S100A8 promoted the healing of skin ulcer by recruiting bone marrow-derived cells to the site of skin ulcer. Furthermore, when HMGB-1 was intravenously administered to cerebral infarction model mice after creation of cerebral infarction, bone marrow-derived cells expressing nerve cell markers were detected in their brain. A marked cerebral infarct-reducing effect was observed in mice intravenously administered with HMGB-1 as compared to the control. The post-cerebral infarction survival rate was increased in the intravenous HMGB-1 administration group. The involvement of bone marrow pluripotent stem cells in the process of bone fracture healing was assessed using mice, and the result demonstrated that bone marrow-derived cells distant from the damaged site migrated to the bone fracture site to repair the damaged tissue.
Abstract: The present invention relates to methods for developing engineered immune cells such as T-cells for immunotherapy that have a higher potential of persistence and/or engraftment in host organism. IN particular, this method involves an inactivation of at least one gene involved in self/non self recognition, combined with a step of contact with at least one non-endogenous immunosuppressive polypeptide. The invention allows the possibility for a standard and affordable adoptive immunotherapy, whereby the risk of GvH is reduced.
Type:
Grant
Filed:
March 11, 2016
Date of Patent:
November 30, 2021
Assignee:
CELLECTIS
Inventors:
Philippe Duchateau, Jean-Pierre Cabaniols, Julien Valton, Laurent Poirot
Abstract: A biodegradable cationic polymer is disclosed, comprising first repeat units derived from a first cyclic carbonyl monomer by ring-opening polymerization, wherein more than 0% of the first repeat units comprise a side chain moiety comprising a quaternary amine group; a subunit derived from a monomeric diol initiator for the ring-opening polymerization; and an optional endcap group. The biodegradable cationic polymers have low cytotoxicity and form complexes with biologically active materials useful in gene therapeutics and drug delivery.
Type:
Grant
Filed:
January 3, 2017
Date of Patent:
November 23, 2021
Assignees:
International Business Machines Corporation, Agency For Science, Technology And Research
Inventors:
Kazuki Fukushima, James L. Hedrick, Yi Yan Yang
Abstract: This invention relates generally to viral vectors and viral particles based on Anelloviruses, which can be used to deliver an agent (e.g., an exogenous effector or an endogenous effector, e.g., a therapeutic effector) to a cell (e.g., a cell in a subject to be treated therapeutically). Described herein are anellosomes, anellovectors, and compositions and uses thereof.
Type:
Grant
Filed:
June 21, 2019
Date of Patent:
November 9, 2021
Assignee:
FLAGSHIP PIONEERING INNOVATIONS V, INC.
Inventors:
Erica Gabrielle Weinstein, Avak Kahvejian, Simon Delagrave, Nathan Lawrence Yozwiak, Kevin James Lebo, Fernando Martin Diaz, Dhananjay Maniklal Nawandar, Ryan D. Tedstone, Jared David Pitts
Abstract: The present invention relates to an isolated transgenic pig beta cell wherein the PKC and the PKA pathway are constitutively activated; to a transgenic pig islet comprising said transgenic pig beta cell; and to a transgenic pig comprising said transgenic pig beta cell or said transgenic pig islet. Another object of the invention is a device comprising a transgenic pig beta cell or a transgenic pig islet of the invention. The present invention also relates to the use of said transgenic pig beta cell, said transgenic pig islet, or said device for treating a disease, disorder or condition related to the impaired function of endocrine pancreas or of beta cell.
Abstract: The present invention relates to a composition comprising secreted extracellular vesicles (SEV) of cells expressing nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 4(NFATC4), for use in the treatment of cancer or in the treatment or prevention of metastatic cancer. It further relates to in vitromethods for determining or predicting the therapeutic efficiency of a treatment with a composition comprising SEV of cells expressing NFATC4 in a cancer patient, based on the ability of the composition comprising SEV of cells expressing NFATC4 to induce an increase in TGF?1 expression level.
Type:
Grant
Filed:
March 29, 2017
Date of Patent:
October 26, 2021
Assignees:
Université de Paris, Institut National de la Sante et de la Recherce Medicale, Assistance Publique—Hopitaux de Paris